Sysmex (OTCMKTS:SSMXY) Updates FY 2025 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.430-0.430 for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.3 billion.

Sysmex Stock Down 9.6%

Shares of OTCMKTS SSMXY traded down $0.90 during trading on Friday, reaching $8.52. The company had a trading volume of 132,855 shares, compared to its average volume of 270,785. Sysmex has a 12-month low of $8.15 and a 12-month high of $19.85. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The business’s 50-day moving average is $9.74 and its 200 day moving average is $11.39. The stock has a market cap of $5.36 billion, a PE ratio of 17.04 and a beta of 1.14.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. As a group, equities analysts forecast that Sysmex will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.